AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03887182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: Additional sequence (DTI) and functional MRI (fMRI) during the MRI which is done as part of the usual care
Study NCT03887182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: functional MRI
Description: Additional sequence (DTI) and functional MRI (fMRI) during the MRI which is done as part of the usual care
Study NCT03887182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Automated Cortical Brainstem Auditory Evoked Potential
Description: Automated Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
Study NCT03887182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Automated Cortical Brainstem Auditory Evoked Potential
Description: Automated Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
Study NCT03887182 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: whole exome sequencing
Description: A study of all the DNA-encoding exons of the child/parent from a sample taken as part of the usual care
Study NCT03887182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cortical Brainstem Auditory Evoked Potential
Description: Standard Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
Study NCT03887182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: multidisciplinary consultation
Description: multidisciplinary consultation is composed of:~* an ENT consultation and audiometry~* a speech therapy assessment~* a psychometric evaluation
Study NCT02378948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid oral feeding
Description: Liquid oral feeding (water, soup, porridge, nutritional supplements etc.)
Study NCT02091414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (MMF)
Description: 1.0 g PO BID
Study NCT02091414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A (CsA)
Description: Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL
Study NCT02091414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: As per the practice of each participating center
Study NCT04350463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab
Study NCT04472598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Tablet; Oral
Study NCT04472598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Tablet; Oral
Study NCT04472598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Tablet; Oral
Study NCT04472598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Navitoclax
Description: Tablet; Oral
Study NCT03825081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine, pilocarpine
Description: 1 drop of pilocarpine (0.5%)~1 drop of brimonidine (0.2%)
Study NCT03850834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammoxetine Hydrochloride Enteric-coated Tablets
Description: There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
Study NCT03850834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo enteric-coated tablets
Description: There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
Study NCT03168451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Text Messages
Description: Members of the intervention group receive culturally tailored messages on the following schedule: 4 messages per day for 1 week prior to target quit date, 4 messages per day for 4 weeks following target quit date, 3 messages per week for 20 weeks following weeks.
Study NCT03821766 — intervention group
Intervention type: DEVICE
Intervention: Ballistocardiography and seismocardiography
Description: SCG and BCG signals will be recorded by the mean of an unobtrusive and friendly device consisting of two houses, the first one placed on the sternum and the second one place on the lumbar region near the subject's center of mass. The signal will be transferred to a tablet by Bluetooth and tracings will be analysed automatically with Matlab. The SCG+BCG signals are synchronized to the intracardiac pressure tracings in order to allow a comparative interpretation between the two tracings.
Study NCT02040753 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intensive Lifestyle Intervention
Description: Intensive Lifestyle intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction. Education within Nutrition, exercise and healthy living in general.
Study NCT02332941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The purpose of this study is to determine if treatment of Age Related Macular Degeneration (AMD) with a new medication,rituximab is effective.
Study NCT00156026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: loop electrosurgical excision procedure (LEEP)
Description: 1. loop electrosurgical excision procedure
Study NCT03628378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verasense
Description: Ligamentous balancing device
Study NCT04135703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Prevention Services + Housing
Description: opioid and related prevention services in addition to 6 months of rental assistance
Study NCT04135703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Prevention Services Only
Description: opioid and related prevention services for 6 months
Study NCT04493853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: 400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Study NCT04493853 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
Study NCT04493853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.
Study NCT04493853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone Acetate
Description: Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.
Study NCT03695601 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Description: Other Standard measures for monitoring rejection: Endomyocardial Biopsy, Echocardiogram, Angiography, Intravascular Ultrasound, Donor-specific HLA Antibody
Study NCT03146741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier
Description: Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
Study NCT01421641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intracervical Lidocaine Injection
Description: Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle
Study NCT01421641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Lidocaine Gel
Description: Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip
Study NCT01881607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESPIRNET Program
Description: The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program.
Study NCT03269903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HILZO esophageal stent
Description: A fully covered esophageal self-expandable metal stent for malignant dysphagia
Study NCT01360346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enteral Sedation (EN)
Description: Intravenous propofol or midazolam administration at the ICU admission and stopped within 48h. Melatonin by enteral route (3mg x 2/die) from admission to discharge. Hydroxyzine by enteral route from ICU admission (600mg/die), decreased and stopped as soon as possible. Lorazepam supplementation (maximum 16mg/die) if hydroxyzine is inadequate.
Study NCT01360346 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group: Intravenous Sedation (IV)
Description: Propofol or midazolam from ICU admission to discharge at the compatible lowest level with harsh ICU environment.
Study NCT03162406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Oral supplementation 25000 IU once per week for 6 months
Study NCT03162406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral supplementation once per week for 6 months
Study NCT03093441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal High-Intensity Interval Training Intervention
Description: The intervention will occur 3 times per week for 12 weeks and include a warm-up, MM-HIIT or R-HIIT training protocol, and a cool down.
Study NCT03093441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal High-Intensity Interval Training Intervention
Description: The intervention will occur 3 times per week for 12 weeks and include a warm-up, MM-HIIT or R-HIIT training protocol, and a cool down.
Study NCT01889368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape Seed Extract
Description: 300 mg capsule of Grape Seed Extract; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
Study NCT01889368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg capsule of maltodextrin; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
Study NCT00661635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5
Study NCT00661635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.
Study NCT00661635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.
Study NCT04001192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise program
Description: The intervention is exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
Study NCT01095627 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metacholine challenge
Description: Exhaled breath analysis following metacholine challenge
Study NCT00837967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler
Description: 160/4.5μg for 3 days
Study NCT00837967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline Turbuhaler
Description: 0.4 mg for 3 days
Study NCT02356952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
Study NCT02356952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Diet
Description: A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
Study NCT02356952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Mediterranean Diet
Description: A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
Study NCT02908152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: 1500 mg~1 capsule / day for 12 weeks
Study NCT02908152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1500 mg~1 capsule / day for 12 weeks
Study NCT02308449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Infusion of 15 mg/kg (up to maximum 1000 mg) ferric carboxymaltose in 250 mL 0.9% sodium chloride
Study NCT02308449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride (placebo)
Description: Infusion of 250 mL 0.9% sodium chloride
Study NCT04211012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus Nab-Paclitaxel +/- cisplatin
Description: Toripalimab injection (JS001): 240mg, i.v.gtt, q3w; Nab-Paclitaxel: 260mg/m2, i.v.gtt, q3w Cisplatin: total dosage of 70 mg/m2 i.v.gtt, q3w，, complete all doses within the first 2 days of each cycle.~Study treatment will be continued until disease progression or intolerable toxicity, or withdrawal at the discretion of the investigator or the subject, loss to follow-up, or initiation of other anti-cancer therapy, or death, whichever occurs first. Toripalimab will be administered no more than 2 years,and nab-paclitaxel with or without cisplatin will be administered up to 6 cycles.. If the subject is intolerable to cisplatin treatment according to the investigator's judgment, JS001 + Nab-Paclitaxel may be dosed.~Dosing sequence: Toripalimab, Nab-Paclitaxel, cisplatin
Study NCT02602314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Study NCT02602314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study NCT04494295 — intervention group
Intervention type: DEVICE
Intervention: Aurora Surgiscope System
Description: MIS evacuation of hematoma using the Aurora Surgiscope System
Study NCT02412176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pacing site - the implantation in the right ventricular (RV) apex
Description: Pacing site - RV apex. The lead will be implanted in the RV apex.
Study NCT02412176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pacing site - the implantation in the septum
Description: Pacing site - septum. The lead will be implanted in the septum.
Study NCT03307941 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Monalizumab
Description: Monalizumab (IPH2201) is given at the recommended dose of 10 mg/kg, intravenously (infusion during 60 minutes) every two weeks
Study NCT03307941 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
Study NCT03307941 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-Fluorouracil
Description: A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
Study NCT03307941 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Metabolic
Description: Radiation therapy must start the first day of FOLFOX chemotherapy. Radiation is given once daily for 5 consecutive days; on the days that the patient receives chemotherapy (and monalizumab when applicable), chemotherapy (and monalizumab) should be given prior to radiotherapy.
Study NCT03307941 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metabolic
Description: 18-FDG-PET scan will be performed just before the beginning of radio-chemotherapy (D10-D14) and will be blinded for investigators and patients. Another 18-FDG-PET will be performed before surgery (surgery Day-5 to surgery Day -1) to exclude metastatic evolution
Study NCT03307941 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Surgery is performed preferably 8 weeks after the completion of the radio-chemotherapy, and it should not be performed less than one week after the last dose of monalizumab
Study NCT02583022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 1.0%
Description: Topical application
Study NCT02583022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAC-14028 cream vehicle
Description: Topical application
Study NCT02583022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel cream 1%
Description: Topical application
Study NCT04579003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization posterolateral glide for 30 secs with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins.
Study NCT04579003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization with movement
Description: Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization with movement (MWM) 10 repetitions with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins.
Study NCT02374424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA101_DHAP
Description: Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.~Scheme of treatment:~* GA101 1000 mg iv day 1, 8, 15 on first cycle (starting from cycle 2, GA101 1000 mg day 1)~* Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles~* Dexamethasone 40 mg day 1-4 of every cycles~* Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy or G-CSF from day 4 till stem cell harvest during mobilization's course (II o III cycle GA101-DHAP)~* GA101 1000 mg iv 24 hours before apheresis as purging in vivo during second courses of therapy
Study NCT01166750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CD-ROM
Description: Treatment Group will continue to follow their treating rheumatologist's recommendations and prescriptions. The program will contain information on the multiple components of pain (the pain puzzle) as a treatment rationale and will then teach children to use cognitive-behavioral techniques for pain management. The information will be presented via visual displays, narration, and interactive menus. Children will be able to navigate through the different lessons at their own pace and will be required to take simple quizzes to assess their learning. Various passwords and homework assignments are embedded within the program to ensure that children are going through the material.
Study NCT01166750 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list Control Group
Description: Children in the control group will continue to follow recommendations and prescriptions by their treating rheumatologist. After an 8-week wait-list control condition that involves measurement phases identical to those of the Jointstrong Treatment Group but no Jointstrong treatment, the children in the control group will enter the Jointstrong program and will then have the same immediate post-treatment measures that the Treatment Group received. The Control Group will not, however, have the Treatment Group's 12-week follow-up phase.